Close Menu
    What's Hot

    Editor’s Letter – Volume 2, Issue 5, May 2026

    May 13, 2026

    Too Early To Judge Impact of New Funded Reinsurance Rules on UK Pension Risk Transfer Market

    May 13, 2026

    Proprietary Reverse Mortgage Market Growth a Welcome Development for MBS Investors

    May 13, 2026
    X (Twitter) LinkedIn
    Longevity & Mortality Investor
    • Home
    • Coverage
      1. Life Insurance Capital Solutions
      2. Life Insurance
      3. Longevity and Mortality Risk Transfer
      4. Mortality
      5. Secondary Life Markets
      6. View All

      Will the US Asset Intensive Life Reinsurance Market Continue Recent Growth Spurt?

      April 22, 2026

      Daiichi Life to Reinsure Whole Life Block with Prismic Life

      April 13, 2026

      Reporting Change to Provide Regulators With More Transparency into US/Offshore Asset-Intensive Life Reinsurance Treaties

      January 28, 2026

      Capital Markets Investors Could Be About to Get a Slice of UK Life Insurance Risk

      November 26, 2025

      Chronic Disease Onset and Cumulative Exposure: Clinical, Prognostic and Underwriting Implications

      May 13, 2026

      US Annuity Sales Notch Tenth Consecutive $100bn+ Quarter

      May 11, 2026

      Life Settlement Secondary Market Returns to Growth but Plenty of Untapped Potential Still Remains

      April 22, 2026

      EIOPA Sets Out Views on Private Equity Ownership of Life Insurers in New Consultation Paper

      March 25, 2026

      Too Early To Judge Impact of New Funded Reinsurance Rules on UK Pension Risk Transfer Market

      May 13, 2026
      Just Group

      Safe Computing Pension Fund Completes Bulk Purchase Annuity Buy-In With Just Group

      May 11, 2026

      Bakkavor Pension Scheme Completes Bulk Purchase Annuity Buy-In With Rothesay

      May 5, 2026
      Bank of England

      Prudential Regulation Authority Publishes New Funded Reinsurance Regulations

      April 29, 2026

      Pricing in the Unknown: Why Mortality Models Aren’t Ready for MCED Tests Just Yet

      April 9, 2026

      Better Understanding of Alzheimer’s Is Improving Lives if Not Actuarial Assumptions – Yet

      March 25, 2026

      Business as Usual in UK Pension Risk Transfer Market Amid Record Low Mortality in England and Wales

      March 25, 2026

      Latest CMI Model Shows Further Rise in Cohort Life Expectancy

      March 11, 2026

      Proprietary Reverse Mortgage Market Growth a Welcome Development for MBS Investors

      May 13, 2026

      Two Years On, PHL Variable Saga Approaches Conclusion

      May 13, 2026

      UK Equity Release Market Origination Slows To Begin 2026

      May 6, 2026

      CHIP Mortgage Trust Issues C$200m of Medium-Term Notes

      April 29, 2026

      Editor’s Letter – Volume 2, Issue 5, May 2026

      May 13, 2026

      Too Early To Judge Impact of New Funded Reinsurance Rules on UK Pension Risk Transfer Market

      May 13, 2026

      Proprietary Reverse Mortgage Market Growth a Welcome Development for MBS Investors

      May 13, 2026

      Two Years On, PHL Variable Saga Approaches Conclusion

      May 13, 2026
    • Events
    • Latest Issues

      Editor’s Letter – Volume 2, Issue 5, May 2026

      May 13, 2026

      Editor’s Letter – Volume 2, Issue 4, April 2026

      April 9, 2026

      Editor’s Letter – Volume 2, Issue 3, March 2026

      March 11, 2026

      Editor’s Letter – Volume 2, Issue 2, February 2026

      February 11, 2026

      Editor’s Letter – Volume 2, Issue 1, January 2026

      January 14, 2026
    • Contact Us
    Newsletter
    Longevity & Mortality Investor

    Long COVID and Reinfection Risk

    Mortality April 13, 2023By Mike Fasano
    Long Covid
    Share
    Twitter LinkedIn Email

    As we enter the 4th year of the COVID-19 pandemic and as the number of infected survivors grows ever larger, attention is increasingly turning to the risks of long COVID and reinfection.

    Characteristics of Long COVID

    Most patients totally recover from acute COVID within 3 to 4 weeks after onset of infection. Long COVID has been reported in 10% to 30% of those with COVID-19,1 and in some studies, even more. It is more common in women, non-whites, hospitalized patients and those with a COPD and/or smoking history. The World Heath Organization characterizes Long COVID, or Post COVID-19 Syndrome, as being associated with:

    • Individuals with a history of probable or confirmed SARS-CoV-2 infection (the virus that causes COVID-19) who experience symptoms impacting everyday life, such as fatigue, shortness of breath and cognitive dysfunction; and

    • Symptoms that usually are present 3 months from the onset of acute COVID-19, that last for at least 2 months and can’t be explained by an alternative diagnosis.

    Interestingly, most with post-COVID syndrome are PCR negative, i.e., they have biologically recovered from acute COVID.2 Approximately 25% of Americans with long COVID report significant activity limitations.3

    Reinfection Risk

    Those infected more than once with SARS-CoV-2 have a higher risk of experiencing diseases associated with long COVID. However, the severity of disease in reinfected people appears to be relatively mild in comparison to those infected only once. A recent V.A. study compared 40,947 people with 2 or more SARS-CoV-2 infections with 443,588 people with only one infection, measuring excess burden and hazard ratios 6 months after reinfection.4

    Excess Burden and Hazard Ratios in reinfected versus singly infected people was as follows:

    Excess Burden and Hazard Ratios for specific impairment groupings measured were as follows:

    Although people with multiple SARS-CoV-2 infections clearly have a higher incidence of respiratory, cardiovascular and neurologic impairments, the severity of the reinfection related impairments is less than that associated with primary infection. A study published in the New England Journal of Medicine (NEJM) found that people experiencing a single infection only experienced severe, critical or fatal disease at more than 10 times the rate of those experiencing multiple infections.5

    The NEJM study was based on a younger, healthier cohort of subjects and therefore not entirely representative of the larger COVID positive population. Nevertheless, the comparative data is directionally instructive:

    Severity of Reinfection versus Primary Infection

    Number with Disease Outcome/Total in Study:

    Conclusions

    We continue to learn more about the long-term risks of COVID-19, but more is still unknown than known. We know that the risk for hospitalized patients is greater, more so for ICU patients. Comorbidities matter and increase risk, particularly COPD and other respiratory impairments. Reinfection increases the risk of impairments, but with diminished potency. We will continue to follow and report on the evolving research.

    Mike Fasano is CEO at Fasano Associates


    Footnotes:

    1Nashville Chest, 2022, Oct 16-19

    2Clinical Research & Reviews, 15(3), 869-875

    3CDC Survey, Sep. 14-26, 2022

    4https://news.feinberg.northwestern.edu/2020/12/04/new-drug-connects-dots-that-cause-clots-in-covid-19-patients/

    5New England Journal of Medicine 2021; 385:2487-24-89

    Any views expressed in this article are those of the author(s) and do not necessarily reflect the views of Life Risk News or its publisher, the European Life Settlement Association

    2023 - April Clinical Mortality Commentary Volume 2 Issue 4 - April 2023
    Share. Twitter LinkedIn Email

    Related Posts

    Chronic Disease Onset and Cumulative Exposure: Clinical, Prognostic and Underwriting Implications

    May 13, 2026By Dr. Jyotsna Kamble

    Pricing in the Unknown: Why Mortality Models Aren’t Ready for MCED Tests Just Yet

    April 9, 2026By Mark McCord

    Better Mortality Analytics Will Unlock the Next Phase of Life Settlement Growth

    April 9, 2026By Liam Bodemeaid

    Better Understanding of Alzheimer’s Is Improving Lives if Not Actuarial Assumptions – Yet

    March 25, 2026By Mark McCord
    Latest Issue

    Too Early To Judge Impact of New Funded Reinsurance Rules on UK Pension Risk Transfer Market

    May 13, 2026

    Proprietary Reverse Mortgage Market Growth a Welcome Development for MBS Investors

    May 13, 2026

    Two Years On, PHL Variable Saga Approaches Conclusion

    May 13, 2026

    Chronic Disease Onset and Cumulative Exposure: Clinical, Prognostic and Underwriting Implications

    May 13, 2026
    Ad

    Where Longevity and Mortality Meet the Markets
    ISSN 2978-5219

    X (Twitter) LinkedIn
    Coverage
    • Life Insurance Capital Solutions
    • Life Insurance
    • Longevity and Mortality Risk Transfer
    • Mortality Risk
    • Secondary Life Markets
    More Info
    • Home
    • About Us
    • Contact Us
    • Guest Articles
    • Submit Story Idea
    Our Newsletter
    Get the latest industry news, commentary and events from the Longevity & Mortality Investor directly into your inbox. Why not sign up today?

    © 2026 Longevity & Mortality Investor. Website by Kavells.
    • Sitemap
    • Privacy Policy
    • Copyright Notice
    • Terms & Conditions

    Type above and press Enter to search. Press Esc to cancel.